α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.1, 2012-01, pp. : 59-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The quest for the treatment of cognitive impairment: α₇ nicotinic and α₅ GABA_A receptor modulators

By Romanelli Maria Novella Gualtieri Fulvio

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 11, 2007-11 ,pp. : 1365-1377

Informa Healthcare

Access to resources Recommend Favorite

Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the 7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 7, Iss. 4, 2007-12 ,pp. : 269-288

Bentham Science Publishers

Access to resources Recommend Favorite

7 Nicotinic Acetylcholine Receptor as a Potential Therapeutic Target for Schizophrenia

Current Pharmaceutical Design, Vol. 17, Iss. 2, 2011-01 ,pp. : 121-129

Bentham Science Publishers

Access to resources Recommend Favorite

α7 Nicotinic Acetylcholine Receptors in Alzheimer’s Disease: Neuroprotective, Neurotrophic or Both?

Current Drug Targets, Vol. 13, Iss. 5, 2012-05 ,pp. : 613-622

Bentham Science Publishers

Access to resources Recommend Favorite

Treating the Cognitive Deficits of Schizophrenia with Alpha4Beta2 Neuronal Nicotinic Receptor Agonists

Current Pharmaceutical Design, Vol. 16, Iss. 3, 2010-01 ,pp. : 309-322

Bentham Science Publishers

Access to resources Recommend Favorite